View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
May 12, 2020

Pharmaceutical professionals say employee safety and supply chain disruption are top Covid-19 concerns

By GlobalData Healthcare

Pharmaceutical industry professionals around the world believe that employee safety and supply chain disruption are their businesses’ top concerns from Covid-19, according to the latest GlobalData survey.

GlobalData’s latest report, Coronavirus Disease 2019 (COVID-19) Sector Impact: Pharmaceutical Trade and Supply Chain Survey – Q1 2020, reveals that 21% of global respondents believe that employee safety will be the biggest impact of Covid-19 on their companies. A total of 20% cite the pandemic’s impact on supply chains as their biggest worry.

The risk of employees catching the disease at work has contributed to concerns about employee safety. Shortages in personal protective equipment (PPE) worldwide are affecting clinical workers, and safety measures during the pandemic make it difficult to move employees between sites. Furthermore, training new, highly skilled employees to replace quarantined workers brings a high cost.

The industry’s other major concerns were clinical trial disruption (cited as the main concern by 16% of respondents), business development (10%), and contract research organization (CRO) disruptions (10%).

The survey revealed differences in business priorities between company types. Concerns about sales representatives’ access to physicians and business development were understandably highest among companies with marketed drugs. These companies need to continue selling their therapies to maintain revenue.

By contrast, companies with drugs in the pipeline but not yet on the market are still in research and development mode, so they expressed more concern with clinical trial disruption, contract research organisation (CRO) disruptions, and money-raising. Because these pipeline-only companies are not yet profitable, they are dependent for money on their ability to raise capital.

Since the first case was diagnosed in Wuhan, China, in December 2019, Covid-19 cases have continued to rise rapidly across the globe. Extreme interventions have been necessary to contain the spread of the virus, resulting in temporary disruption to pharmaceutical supply chains in some regions.

Across all company types and regions, 92% of those surveyed say Covid-19 poses a risk to their companies’ imports / exports.

A total of 136 pharma company staff from around the world, including C-level executives, participated in the survey, which was fielded from 13 March 2020 to 24 March 2020.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU